Cargando…

Strategies to Target ISG15 and USP18 Toward Therapeutic Applications

The interferon (IFN)-stimulated gene product 15 (ISG15) represents an ubiquitin-like protein (Ubl), which in a process termed ISGylation can be covalently linked to target substrates via a cascade of E1, E2, and E3 enzymes. Furthermore, ISG15 exerts functions in its free form both, as an intracellul...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez Fernández, Daniel, Hess, Sandra, Knobeloch, Klaus-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985271/
https://www.ncbi.nlm.nih.gov/pubmed/32039148
http://dx.doi.org/10.3389/fchem.2019.00923
_version_ 1783491786980720640
author Jiménez Fernández, Daniel
Hess, Sandra
Knobeloch, Klaus-Peter
author_facet Jiménez Fernández, Daniel
Hess, Sandra
Knobeloch, Klaus-Peter
author_sort Jiménez Fernández, Daniel
collection PubMed
description The interferon (IFN)-stimulated gene product 15 (ISG15) represents an ubiquitin-like protein (Ubl), which in a process termed ISGylation can be covalently linked to target substrates via a cascade of E1, E2, and E3 enzymes. Furthermore, ISG15 exerts functions in its free form both, as an intracellular and as a secreted protein. In agreement with its role as a type I IFN effector, most functions of ISG15 and ISGylation are linked to the anti-pathogenic response. However, also key roles in other cellular processes such as protein translation, cytoskeleton dynamics, exosome secretion, autophagy or genome stability and cancer were described. Ubiquitin-specific protease 18 (USP18) constitutes the major ISG15 specific protease which counteracts ISG15 conjugation. Remarkably, USP18 also functions as a critical negative regulator of the IFN response irrespective of its enzymatic activity. Concordantly, lack of USP18 function causes fatal interferonopathies in humans and mice. The negative regulatory function of USP18 in IFN signaling is regulated by various protein–protein interactions and its stability is controlled via proteasomal degradation. The broad repertoire of physiological functions and regulation of ISG15 and USP18 offers a variety of potential intervention strategies which might be of therapeutic use. Due to the high mutation rates of pathogens which are often species specific and constantly give rise to a variety of immune evasion mechanisms, immune effector systems are under constant evolutionarily pressure. Therefore, it is not surprising that considerable differences in ISG15 with respect to function and sequence exist even among closely related species. Hence, it is essential to thoroughly evaluate the translational potential of results obtained in model organisms especially for therapeutic strategies. This review covers existing and conceptual assay systems to target and identify modulators of ISG15, ISGylation, USP18 function, and protein–protein interactions within this context. Strategies comprise mouse models for translational perspectives, cell-based and biochemical assays as well as chemical probes.
format Online
Article
Text
id pubmed-6985271
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69852712020-02-07 Strategies to Target ISG15 and USP18 Toward Therapeutic Applications Jiménez Fernández, Daniel Hess, Sandra Knobeloch, Klaus-Peter Front Chem Chemistry The interferon (IFN)-stimulated gene product 15 (ISG15) represents an ubiquitin-like protein (Ubl), which in a process termed ISGylation can be covalently linked to target substrates via a cascade of E1, E2, and E3 enzymes. Furthermore, ISG15 exerts functions in its free form both, as an intracellular and as a secreted protein. In agreement with its role as a type I IFN effector, most functions of ISG15 and ISGylation are linked to the anti-pathogenic response. However, also key roles in other cellular processes such as protein translation, cytoskeleton dynamics, exosome secretion, autophagy or genome stability and cancer were described. Ubiquitin-specific protease 18 (USP18) constitutes the major ISG15 specific protease which counteracts ISG15 conjugation. Remarkably, USP18 also functions as a critical negative regulator of the IFN response irrespective of its enzymatic activity. Concordantly, lack of USP18 function causes fatal interferonopathies in humans and mice. The negative regulatory function of USP18 in IFN signaling is regulated by various protein–protein interactions and its stability is controlled via proteasomal degradation. The broad repertoire of physiological functions and regulation of ISG15 and USP18 offers a variety of potential intervention strategies which might be of therapeutic use. Due to the high mutation rates of pathogens which are often species specific and constantly give rise to a variety of immune evasion mechanisms, immune effector systems are under constant evolutionarily pressure. Therefore, it is not surprising that considerable differences in ISG15 with respect to function and sequence exist even among closely related species. Hence, it is essential to thoroughly evaluate the translational potential of results obtained in model organisms especially for therapeutic strategies. This review covers existing and conceptual assay systems to target and identify modulators of ISG15, ISGylation, USP18 function, and protein–protein interactions within this context. Strategies comprise mouse models for translational perspectives, cell-based and biochemical assays as well as chemical probes. Frontiers Media S.A. 2020-01-21 /pmc/articles/PMC6985271/ /pubmed/32039148 http://dx.doi.org/10.3389/fchem.2019.00923 Text en Copyright © 2020 Jiménez Fernández, Hess and Knobeloch. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Jiménez Fernández, Daniel
Hess, Sandra
Knobeloch, Klaus-Peter
Strategies to Target ISG15 and USP18 Toward Therapeutic Applications
title Strategies to Target ISG15 and USP18 Toward Therapeutic Applications
title_full Strategies to Target ISG15 and USP18 Toward Therapeutic Applications
title_fullStr Strategies to Target ISG15 and USP18 Toward Therapeutic Applications
title_full_unstemmed Strategies to Target ISG15 and USP18 Toward Therapeutic Applications
title_short Strategies to Target ISG15 and USP18 Toward Therapeutic Applications
title_sort strategies to target isg15 and usp18 toward therapeutic applications
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985271/
https://www.ncbi.nlm.nih.gov/pubmed/32039148
http://dx.doi.org/10.3389/fchem.2019.00923
work_keys_str_mv AT jimenezfernandezdaniel strategiestotargetisg15andusp18towardtherapeuticapplications
AT hesssandra strategiestotargetisg15andusp18towardtherapeuticapplications
AT knobelochklauspeter strategiestotargetisg15andusp18towardtherapeuticapplications